Regulatory T cells (Tregs) play a potential role in operational tolerance in liver transplantation (LT) patients, and microRNAs (miRNAs) are known to be involved in immunological responses and tolerance. Thus, we analyzed the implication of different peripheral blood Treg subsets and miRNAs on LT tolerance in 24 tolerant (Tol) and 23 non-tolerant (non-Tol) LT recipients by cellular, genetic, and epigenetic approximation. Non-Tol patients had a lower demethylation rate of the forkhead box P3 (FOXP3) regulatory T cell-specific demethylated region (TSDR) than Tol patients that correlated with the frequency of circulating Tregs. Tol patients presented a different signature of Treg subset markers compared with non-Tol patients with increased expression of HELIOS and FOXP3 and a higher proportion of latency-associated peptide (LAP)
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The achievement of immune tolerance to an allogenic graft has been a field of intense research over the last decades, fueled by a critical need to avoid immunosuppression (IS)-related side effects. Regulatory T cells (Tregs) that promote a state of antigen-specific peripheral tolerance by suppressing the activation and expansion of reactive effector cells have been implicated in this process. (1) Tregs are characterized by forkhead box P3 (FOXP3) expression, but they are not a homogeneous subset of cells. Tregs can be subdivided into naturally occurring regulatory T cells (nTregs), which develop in the thymus, and adaptive or induced regulatory T cells (iTregs), which are converted from CD4
1 CD25 -FOXP3 -T cells in peripheral blood. (2) Although molecules such as neuropilin-1 (NRP-1) (3) and HELIOS, an IKAROS transcription factor family member, (4) have been proposed to be selectively expressed on nTregs but not on in vivo or in vitro generated iTregs, it is difficult to distinguish between nTregs and iTregs, and it is also not clear whether both subsets are required for transplantation tolerance or whether 1 subset predominates over the other. (5) Even more, these subsets can be subdivided using other markers such as inducible T cell costimulator (ICOS; or CD278), which defines a population of Tregs that produce interleukin (IL) 10 and transforming growth factor b (TGF-b; ICOS 1 ) or only TGF-b (ICOS -). (6) The stable expression of FOXP3 in naturally occurring Tregs requires DNA methylation-based regulation. (7) Demethylation at a highly conserved region within the human FOXP3 gene (regulatory T cell-specific demethylated region [TSDR] ) was found to be restricted to Tregs. (8) In addition to the high specificity for Tregs, it has also been observed that FOXP3 TSDR demethylation occurred only in nTregs, but not in recently activated effector T cells that transiently express FOXP3. (9) In recent years, microRNAs (miRNAs) have risen as RNAs with a high potential prognostic value. miRNAs are small (21-25 nucleotides) double-stranded noncoding RNAs that can regulate the expression of several genes by reducing the ability of specific messenger RNAs (mRNAs) to lead the synthesis of the proteins they encode. (10) Many miRNAs that are involved in the regulation of the immune system have been described, demonstrating that these miRNAs modulate many aspects of the immune response, including differentiation, the survival and function of immune cells, the response to cytokines and cell signaling pathways. (11, 12) It has even been proposed that several miRNAs are a direct target of FOXP3 and may partly control the function, development, and homeostasis of Tregs. Likewise, they might also be excellent biomarkers of allograft injury and function. (13, 14) The aim of this study was to determine the influence of the different Treg subsets and miRNAs on transplantation tolerance. For this purpose, we used different approaches to reveal significant differences in the distribution of these cell subsets and gene expression patterns, including those of miRNAs, in blood samples obtained retrospectively from non-Tol (nontolerant) and operationally tolerant (Tol) liver recipients after successful IS withdrawal.
Patients and Methods

PATIENTS
All of the 47 patients who participated in the present study came from 4 immunosuppressive drug withdrawal trials previously performed at Hospital Universitario Virgen de la Arrixaca (Murcia, Spain) and Cl ınica Universidad de Navarra (Pamplona, Spain) between 2000 and 2013 (Table 1) . Candidacy criteria for the inclusion of these patients in those trials were as follows:
1. Liver recipients with a functioning allograft for >2 years. 2. At least 1 year without a documented rejection episode. 3. The absence of cancer or autoimmune liver disease before liver transplantation (LT).
IS was gradually withdrawn in 10% decrements at 1-month intervals as long as the liver function was stable, and the patients were monitored monthly for liver graft dysfunction. Some of the patients suffered a rejection episode during the IS withdrawal process and were treated by reintroducing the immunosuppressive therapy that they had been receiving before the beginning of the weaning protocol (non-Tol patients); other patients became Tol (no IS and normal allograft function at least 1 year after IS withdrawal). Liver rejection was indicated by high serum levels of aspartate aminotransferase (AST) or alanine aminotransferase (ALT) and confirmed by liver biopsy. The diagnosis of cellular rejection was based on the presence of predominantly mononuclear portal infiltrate plus nonsuppurative ductal cholangitis with or without endothelitis.
target of rapamycin inhibitor; n.a., not available; non-Tol, nontolerant; NRP-1, neuropilin-1; nTreg, naturally occurring regulatory T cell; PBMC, peripheral blood mononuclear cell; PSC, primary sclerosing cholangitis; qRT-PCR, quantitative reverse transcription-polymerase chain reaction; R, rejection sample; RNU6B, U6 small nuclear RNA B; SE, standard error; SSC-A, side scatter area; STAT1, signal transducer and activator of transcription 1; Tac, tacrolimus; TCR, T cell receptor; TET2, tet methylcytosine dioxygenase 2; TGF-b, transforming growth factor b; T h 1, T helper 1; Tol, tolerant; Treg, regulatory T cell; TSDR, regulatory T cell-specific demethylated region; V0, basal sample; Vf, final sample.
BLOOD SAMPLES
All blood samples were obtained under informed consent, and the study was approved by the ethical committees of both hospitals (PI12/02042 and 28-2015) and conforms to the ethical guidelines of the 1975 Declaration of Helsinki.
The samples used in this work were divided into 2 types:
1. Retrospective Samples: Samples from the 47 patients participating in the study were collected during a 1-year period and later analyzed. All of the samples belong to a postrejection (non-Tol group) or posttolerance (Tol group) time point. The minimum postrejection or postwithdrawal time was 1 year, with a mean of 64 years in both groups and a range of 1 to 15 years and 1 to 12 years, respectively ( Table 2) . A clear bias toward male patients did exist in both groups, but it was similarly applied to healthy donors. However, there was a statistically significant difference in age between the healthy subjects and patients; 72.3% of the transplant patients received calcineurin inhibitors (CNIs) as a basal IS. The nonTol group was more uniform with 95.7% of the patients receiving a single therapy of CNIs compared with 75% of the Tol group (21% received dual therapy; Table 2 ). These data are in accordance with a significantly longer time between the transplant and the start of the weaning trial in the Tol group (Table  2 ). 2. Prospective Samples: Unfortunately, only 10 non-Tol and 4 Tol patient samples from 3 different time points during the IS withdrawal process were available for the study. These samples came from the last clinical trial conducted in 2012-2013 (Tables 1 and  3 ). The basal sample (V0) is a baseline sample collected from the 14 patients before starting the IS withdrawal process; the rejection sample (R) was collected from the 10 non-Tol patients when they suffered a rejection episode during the IS withdrawal process, whereas the final sample (Vf) is an endpoint sample that corresponds to the "retrospective" sample for each patient as explained above.
Samples from 16 nontransplant healthy volunteers were obtained and treated in a similar manner as the patient samples.
FLOW CYTOMETRY
Frozen peripheral blood mononuclear cells (PBMCs) were thawed and washed. Before cell staining, the dead cells were removed using a Dead Cell Removal Kit After staining, the cells were subjected to flow cytometry analysis in a BD FACSCanto flow cytometer and FACSDiva software (BD Biosciences, San Jose, CA) by gating for singlets based on the forward scatter area (FSC-A), forward scatter height (FSC-H), and side scatter area (SSC-A) parameters; 100,000 PBMC gated events were acquired. The frequency of the different Treg subpopulations was determined using the FCS Express 4 software (DeNovo Software, Glendale, CA).
QUANTITATIVE REVERSE TRANSCRIPTION-POLYMERASE CHAIN REACTION
Total RNA was extracted from stabilized whole blood using the PAXgene Blood miRNA Kit (PreAnalytiX, Hombrechtikon, Switzerland), followed by reverse transcription; quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was performed using SYBR Premix ExTaq (Takara, Mountain View, CA) for mRNA and the SYBR Green polymerase chain reaction kit (Qiagen, Hilden, Germany) for miRNA. Primers specific to the mRNA and miRNA were purchased from Qiagen.
The samples were run in duplicate, and the relative gene expression levels were calculated using the 2 -DCt method, normalizing to glyceraldehyde 3-phosphate dehydrogenase and hypoxanthine-guanine phosphoribosyltransferase for mRNA and U6 small nuclear RNA B (RNU6B) for miRNA.
DETERMINATION OF THE DEGREE OF FOXP3 TSDR DEMETHYLATION BY METHYL-SPECIFIC QUANTITATIVE POLYMERASE CHAIN REACTION
Genomic DNA was extracted from buffy coats using the QIAmp DNA Blood Mini Kit (Qiagen). The DNA was then bisulfite converted using the Epitec Bisulfite Kit (Qiagen), and the degree of FOXP3 TSDR demethylation was determined by methyl-specific quantitative polymerase chain reaction (MS-qPCR). The methylationand demethylation-specific primers, cycling conditions, and demethylation rate (DMR) calculations were described previously. (15) For female patients, DMR was corrected by a factor of 2 because 1 of the 2 TSDR alleles was methylated as a result of X-inactivation.
STATISTICAL ANALYSIS
Continuous variables were tested for normal distribution by the Kolmogorov-Smirnov test. The homogeneity of variances (homoscedasticity) was analyzed with the F test. An analysis of variance with Bonferroni's posttest was used whenever parametrical testing applied (normal distribution and homoscedasticity), and the Kruskal-Wallis test with Dunn's posttest was used when the data set had to be analyzed with a nonparametric test. A Wilcoxonrank test or Friedman test was used to compare related samples when indicated. Two-tailed P values < 0.05 were regarded as significant. Correlation analyses were evaluated using Spearman's correlation. The statistical analysis was performed using the statistical package for social sciences software (SPSS 21.0 for Windows, SPSS Inc.).
Results
NON-TOL PATIENTS HAVE A LOWER TSDR-DMR THAT CORRELATES WITH THE FREQUENCY OF TREGS
The presence of Tregs in the blood can be reported as the total number, the total frequency (percentage), or the ratio in relation to total CD4 1 T cells. However, the quantification of the FOXP3 TSDR-DMR is becoming the gold standard for Treg detection. This method revealed that non-Tol patients had a lower degree of TSDR demethylation compared with both healthy and Tol patients (Fig. 1A) . Moreover, it has been shown that DNA demethylase tet methylcytosine dioxygenase 2 (TET2) binds to the TSDR of the FOXP3 locus, and it is up-regulated by T cell receptor (TCR) signaling, which is required for FOXP3 stability. (16) However, we did not observe a relationship between TET2 expression and tolerance because no difference was found between the Tol and non-Tol groups (Fig. 1B) .
Nevertheless, the TSDR-DMR showed a similar profile and a statistically significant positive correlation (r 5 0.572; P < 0.001) with the frequency of Tregs (Fig.  1C,D) .
TOL PATIENTS PRESENT A DIFFERENT SIGNATURE OF TREG SUBSET MARKERS COMPARED WITH NON-TOL
In an attempt to determine the profile of the different Treg subsets, several markers were analyzed in Tol and non-Tol patients as well as in healthy donors. At the level of mRNA expression, only 2 of the 9 analyzed genes, HELIOS and FOXP3, were significantly different between both groups of patients, whereas 
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high CD127 low/-staining. (D) Spearman's correlation between different variables. (A) represents statistically significant differences between the Tol and non-Tol group, whereas (B) represents statistically significant differences in relation to the healthy group. *P 0.05; **P 0.01; ***P 0.001. CD31, IL1R1, IL1R2, TGF-b1, and NRP-1 did not change ( Fig. 2A) . A lower expression of both genes was observed in the non-Tol group, but the expression levels in the Tol group were similar to those in the healthy group. Regarding the Treg cell markers analyzed by flow cytometry, only Tregs expressing LAP or ICOS, but not CD31 or HELIOS (Fig. 2B) , showed a difference between the patient groups. Again, the percentage of LAP 1 Tregs was higher in the Tol group than in the non-Tol group, but it was similar to that in the healthy group. Interestingly, the percentage of Tregs expressing surface ICOS was lower in the Tol group, even compared with the healthy group.
Tregs can be identified as naive (CD45RA 1 ) or effector-memory (CD45RA -) cells. No differences in the number of these subsets were found among the groups (Fig. 3A) . However, when the activation of effector-memory Tregs was analyzed using HLA-DR as surface marker, we observed that non-Tol patients had fewer circulating activated effector-memory Tregs than the Tol and healthy groups (Fig. 3B) .
TOL AND NON-TOL PATIENTS SHOW DIFFERENCES IN miRNA EXPRESSION
To investigate the role of miRNAs in LT tolerance, we analyzed the expression of 8 miRNAs in whole blood. These miRNAs had been described previously in the literature as being directly related to Tregs function, and they may directly target the FOXP3 gene. As shown in Figs. 4-5 these miRNAs (miR95, miR24, miR31, miR146a, and miR155) showed differential expression in both groups of patients, whereas the other 3 miRNAs (miR142-3p, miR21, and miR210) did not. All of the miRNAs that showed statistically significant differences had a higher expression in the Tol patients than in the non-Tol group. However, only the expression of miR146a was significantly different between the Tol patients and the healthy group, with the higher expression being in the latter group (Fig. 4) . 
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high CD127 low/-) that expresses LAP (TGF-b1), ICOS, CD31, or HELIOS as determined by flow cytometry from PBMCs. (A) represents statistically significant differences between the Tol and non-Tol group, whereas (B) represents statistically significant differences in relation to the healthy group. *P 0.05; **P 0.01; ***P 0.001.
THE MINIMIZATION OF IS DOES NOT CORRELATE WITH THE EVOLUTION OF THE VARIABLES IN NON-TOL PATIENTS
With the aim of elucidating whether the study findings are a result of the presence or absence of IS drugs, we analyzed prospective samples from 10 non-Tol and 4 Tol patients at the basal (V0; before weaning) and rejection (R; only for the non-Tol group) points and compared these samples with those obtained for the retrospective study (Vf). As shown in Fig. 5 , IS minimization was not correlated with the evolution of the variables in the non-Tol group. Only the TSDR-DMR was different between the samples that had received high doses of IS (V0 and Vf) and the samples that had received lower concentration (R). However, the Tol group had a tendency to show up-regulation of any variable when the IS -Tregs (effector-memory Tregs) that express HLA-DR (activated effector-memory Tregs) as determined by flow cytometry from PBMCs. (A) represents statistically significant differences between the Tol and non-Tol group, whereas (B) represents statistically significant differences compared with the healthy group. ***P 0.001.
FIG. 4.
Tol and non-Tol patients display different miRNA expression profiles. The relative expression of miR95, miR24, miR31, miR146a, miR155, miR142-3p, miR21, and miR210 as determined by qRT-PCR from stabilized whole blood. (A) represents statistically significant differences between the Tol and non-Tol group, whereas (B) represents statistically significant differences compared with the healthy group. *P 0.05; **P 0.01; ***P 0.001. was completely removed (Vf), but only the Treg frequency and the ICOS 1 or LAP 1 Tregs were significantly different in this group compared with the V0 sample. Moreover, Tol patients had a significantly lower frequency of ICOS 1 Tregs at the V0 basal time point (Fig. 5) .
HIERARCHICAL CLUSTERING ANALYSIS OF THE STUDIED VARIABLES GROUPS DATA IN 2 DIFFERENTIATED CLUSTERS
To achieve a global view of the analyzed variables in this study, we analyzed the data obtained from the non-Tol and Tol patients using the Gene Cluster 3.0 software and generated a heat map using Java TreeView, version 1.1.6r4 open software (Fig. 6A) . From this analysis, we identified at least 2 clear clusters of variables. Although cluster A could be described as a "miRNA cluster," cluster B could be defined as an "activated Treg cluster." The cluster B variables are shown as a distinguishing element between both states and are more clearly expressed in the Tol group. However, this is more difficult to asseverate for cluster A. All of the miRNA studied, except for miR210, were included in cluster A, and it is important to note that miR155 and miR24 show a high correlation with The concentration of IS drug in the blood was plotted as data normalized with respect to the highest concentration (Tac 5 12 ng/mL; cyclosporine 5 68 ng/mL). The Tol and non-Tol group differences were analyzed using a Wilcoxon-rank test or a Friedman test, respectively. (A) represents statistically significant differences in each group of patient samples with respect to the V0 sample, whereas (B) represents statistically significant differences in the non-Tol patient samples with respect to the R data point. The vertical line in the ICOS 1 Treg cell graph represents the significant difference for that parameter at the V0 time point between the Tol and non-Tol groups. *P 0.05; **P 0.01; ***P 0.001. each other (r 5 0.833; P < 0.001) as well as with miR146a (r 5 0.828; P < 0.001). The percentage of activated effector-memory Tregs (Act_Eff_Mem_-Treg), the frequency of Tregs expressing LAP (LAP_FC), and the expression of HELIOS and FOXP3 (HELIOS_Q and FOXP3_Q) are included in cluster B. We can highlight the correlation between activated Tregs and LAP 1 Tregs (r 5 0.595; P < 0.01) and between the expression of HELIOS and FOXP3 (r 5 0.778; P < 0.001). Both clusters appear to be correlated (r 5 0.477; P < 0.05). Interestingly, when analyzed individually, most of the miRNAs that are differentially expressed in Tol patients showed a positive correlation with the variables grouped in the cluster of activated Tregs, overall with activated effector-memory CD45RA -HLA-DR 1 and LAP 1 Tregs (Fig. 6B ).
Discussion
Many studies have emphasized the genetic and phenotypic profile of blood or tissue samples from tolerant transplant patients. This approach has given great results, overall clarifying the involvement of FOXP3 1 Tregs in this phenomenon beyond other actors such as B cells, natural killer cells, and cdTCR cells as well as liver iron metabolism. (17) However, it is well established that Tregs are not a homogeneous subset of cells. Tregs can be subdivided into nTregs and iTregs, which develop in the thymus or in the periphery, respectively.
(2) Several markers, (4, 5) in addition to the highly specific FOXP3 TSDR demethylation in nTregs, (8, 9) have been proposed to distinguish both subsets. Furthermore, nTregs can be subdivided using other markers. (6, 18) However, little is known about the profile and frequency of these Treg cell subsets or their markers in clinical transplantation tolerance.
This work was performed retrospectively on a cohort of 47 Tol and non-Tol LT patients selected from 4 IS weaning clinical trials. In accordance with previous studies, Tol patients had a significantly longer time from transplant to weaning start (19, 20) and had a higher expression of FOXP3 mRNA. (21) The analysis of the degree of FOXP3 TSDR methylation is a new tool for the quantitation of Tregs in peripheral blood or solid tissue in different diseases. (9, 15) Although a higher DMR at the FOXP3 locus in sorted CD4
1 T cells from Tol kidney transplant patients has been previously shown, (22) our work used a simplified technique starting from whole blood to show similar results in LT patients. Although this result was correlated with the peripheral blood frequency of Tregs, it might better describe an active nTreg cell subset, because the suppressive function of Tregs is dependent on the stability of FOXP3, (23) and there was only a difference in TSDR demethylation in sorted CD45RA
-memory Tregs but not in total Tregs. (22) Although we have not found any differences in the frequency of CD45RA -Tregs between the groups, it is worth noting that the activated cell frequency in the effector-memory Treg cell subset detected by HLA-DR staining was higher in LT Tol. LAP is up-regulated on activated Tregs and has been detected on megakaryocytes and immature dendritic cells. HELIOS expression also appears to be closely related to activated cells. HELIOS is an IKAROS transcription factor family member, which is preferentially expressed at the mRNA level in Tregs. (26) Although HELIOS was initially proposed to be a potential marker of nTregs, (4) it has been associated with T cell activation (27) and is thought to be a marker of activated Tregs expressing LAP. (28) We were not able to show differences in the frequency of HELIOS 1 Tregs, perhaps due to the complexity of the intracellular staining protocol or the selected antibody clone. Although only the relative expression of HELIOS mRNA was significantly different in Tol patients, our results nevertheless suggest the idea of HELIOS as an activation marker for Tregs. However, this activation profile does not fit perfectly with the one obtained for the frequency of ICOS 1 Tregs. ICOS is a member of the CD28 and cytotoxic T lymphocyte antigen 4 (CTLA-4) cell surface receptor family, which is absent in naive human T cells but can be induced in activated human T cells, including Tregs. (29) In addition, ICOS signaling is required for the expansion of FOXP3
1 Tregs following antigen challenge. (30) However, our results indicate a lower frequency of ICOS 1 Tregs in the Tol group, even at the basal time point, and a low correlation with the other activation markers that are expressed higher in this state. A possible explanation can be found in the results obtained by Ito et al. (6) which showed that ICOS 1 Tregs displayed a strong tendency to undergo rapid apoptosis, unless signaled by the ICOS ligand, whereas ICOS -Tregs did not display such a propensity for apoptosis. We also found a set of miRNAs that were upregulated in the peripheral blood of LT Tol patients and nearly related to Treg activation markers. nTregs have miRNA profiles that are distinct from conventional CD4
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2 cells, and the FOXP3 transcription factor contributes to the miRNA profile. (11) From this set, we could highlight a significant correlation among miR155, miR24, and miR146a. miR155 is constitutively highly expressed in Tregs and is of particular interest because FOXP3 binds to the promoter of its gene B cell Integration Cluster and controls the elevated miR155 expression required for maintaining Treg cell proliferative activity and numbers under nonlymphopenic conditions. miR155 has also been linked to antibody production, cytokine production, TLR signaling and Treg generation, (13) and its expression in nTregs and conventional T cells increases remarkably after stimulation. (31) Moreover, miR155 2/2 mice have reduced numbers of Tregs. (32) Similar to miR155, miR146a is highly expressed in Tregs and is induced upon activation. This miRNA is essential for the ability of Tregs to suppress T helper 1 (T h 1) responses by the down-regulation of signal transducer and activator of transcription 1 (STAT1), a key transcription factor required for T h 1 effector cell differentiation. (33) Moreover, miR146a is overexpressed and is involved in spontaneous tolerance in murine hepatic allografts. (34) In this way, miR95 positively regulates FOXP3 expression via an indirect mechanism, whereas miR24 is downregulated in Tregs and negatively controls FOXP3 expression by directly binding to its potential target site in the 3 0 untranslated region of FOXP3 mRNA. (35, 36) Therefore, the consistent cluster formed by miRNA in our study is not surprising, and, although contradictory, our results could indicate an attempt to balance the activation of the Tregs between miRNAs that up-regulate FOXP3 expression and miRNAs that negatively regulate its expression. Danger et al. (37) have already reported the modulation of the expression of 8 miRNAs, including miR142-3p, in PBMCs from Tol kidney graft recipients. We did not find the same differences in LT patients, but it has been described that liver and kidney Tol recipients differ in blood expression and B cell immunophenotypic patterns, and no significant overlap has been detected between them. (38, 39) Because of the finding that almost every variable that was differentially expressed in the Tol group followed a similar profile to the healthy group independent of the age differences between the groups, it is tempting to speculate that the IS drugs might mask the results. However, the posterior analysis of the prospective samples from 14 patients who underwent IS withdrawal showed that the Tol patients tended to up-regulate all of the variables from baseline to complete withdrawal, whereas the non-Tol patients did not present differences when IS was diminished. Likewise, there was no correlation between the elapsed time from weaning to sample collection in any of the cited variables (data not shown). Nevertheless, previous works have pointed in this way for tolerance biomarkers such as FOXP3 expression (21) or miR142-3p. (37) Our data reinforce the idea that activated effectormemory Tregs may play a role in the complex system of regulation of LT tolerance. In addition, and beyond the classical glucocorticoid-induced TNFR family related gene (GITR), cytotoxic T-lymphocyte antigen 4 (CTLA-4) and lymphocyte-activation gene 3 (LAG3) markers, we show the capacity of new activation markers to differentiate an operational tolerance state and the possibility that these markers are delimiting different subsets of activated Tregs. Likewise, the present study has evidenced the utility of whole blood TSDR-DMR determination as an easy tool for characterizing a Treg subset implied in the regulation of LT tolerance. Our study also identified a set of miRNAs that are differentially expressed in human LT Tol patients and that may promote and control the activation of Tregs that is necessary to develop and/or maintain transplantation operational tolerance. However, the limitation of the study design (retrospective nature of the study, small number of patients with complete data, and heterogeneity in the cohort) necessitates the further study of these Treg subsets and miRNAs in well-controlled and larger prospective trials.
